CLL combos coming, melanoma semblances only skin deep
As researchers and clinicians converge on New Orleans for the annual meeting of the American Society of Hematology (ASH) this weekend, one thing is clear: There will be a bumper crop of data on drugs for the treatment of chronic lymphocytic leukemia (CLL). The society itself is putting on a press briefing on “the changing landscape of CLL.” One of the most anticipated presentations will be the Sunday plenary session showing the direct comparison of Rituxan (rituximab, Biogen Idec Inc.) to newly approved Gazyva (obinutuzumab, Roche AG), formerly GA101, which was approved in November on the basis of data comparing it to chlorambucil.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter